Delong Liu, MD, PhD

Love golfing

[Chinese American Hematologist & Oncologist Network @CAHON_hemonc]

We extend our heartfelt thanks to all the dedicated professionals who contributed to the success of the 11th New York Oncology Forum! Your insights and collaboration are advancing cancer care and fostering innovation. Together, we’re pushing boundaries, strengthening partnerships, raising the standard of care, and making a lasting impact in our field. NYOF, one of CAHON’s flagship events, takes place annually during the first weekend of October. We look forward to seeing you at the 12th NYOF. #NYOF #CAHON #CancerResearch

[Delong Liu, MD, PhD @JHOeditor]

@CAHON_hemonc JHO is the official journal of CAHON!

[Paperbirds_Hematology @PaperbirdsM]

New article: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting https://t.co/D5MMWk0t2f #MMSM #MultipleMyeloma #hematology

[Delong Liu, MD, PhD @JHOeditor]

https://t.co/fuE1suGvoa

[TOC Foundation （Official） @FoundationToc]

Chinese-Americans, Facing Abuse, Unite to Aid Hospitals in Coronavirus Battle https://t.co/woWV2wpPT6 #StrongerTogether #InThisTogether #TOCF #TOCFoundation
#ChineseCommunity
#GuardingTheAngels
#ChineseAmericanFightCovid19
#GetUSPPE #PPEShortages You Defend Us. We Defend You.

[Delong Liu, MD, PhD @JHOeditor]

ScienceTake | Ice Fish Don’t Melt https://t.co/jTV5uNW3vf via @nytvideo

[Delong Liu, MD, PhD @JHOeditor]

Universal CAR T trials, PALL and CALM, revealed very mild GVHD (grade I). https://t.co/C0e81UZYNn

[Delong Liu, MD, PhD @JHOeditor]

miniHCVD-INO-blinatumomab regimen for acute lymphoblastic leukemia. https://t.co/gVLuWORvaZ

[Delong Liu, MD, PhD @JHOeditor]

miniHCVD-INO-blinatumomab will be a key regimen for ALL therapy!!! Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia https://t.co/K4qmuBLISp

[Delong Liu, MD, PhD @JHOeditor]

The first PD-1 antibody originated from China got approved in CHina.
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients https://t.co/pp0P1h3MJP

[Delong Liu, MD, PhD @JHOeditor]

What does Lunar New Year mean to you? - South China Morning Post https://t.co/lscZ5Dc5Zu

[Delong Liu, MD, PhD @JHOeditor]

This was presented at ASCO and ASH, data finally published!!! A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma https://t.co/f2CuZy8oSq

[Delong Liu, MD, PhD @JHOeditor]

Siglec-15 was disclosed in this update meeting and data just published in Cell by Lieping Chen. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing https://t.co/hRX7U9Ssvi

[Delong Liu, MD, PhD @JHOeditor]

Universal CARs, universal T cells, and universal CAR T cells https://t.co/6Vxlob1Prl

[Delong Liu, MD, PhD @JHOeditor]

Cytokine release syndrome: grading, modeling, and new therapy https://t.co/S1Aae7L2D5.
Anti-IL1R therapy looks promising for CRS/CRES prevention and therapy. Clinical trials are coming! Separation of CRS and CART cell function --another major finding! Trials underway!

[Delong Liu, MD, PhD @JHOeditor]

Platelets are increasingly known to be involved in carcinogenesis and metastasis!!!
Role of platelets and platelet receptors in cancer metastasis https://t.co/Gkkjj7iwa6

[Delong Liu, MD, PhD @JHOeditor]

Daratumumab safe on mobilized CD34+ cells of myeloma patients in… https://t.co/NWarXmUKmL

[Delong Liu, MD, PhD @JHOeditor]

Organoid technology and applications in cancer research https://t.co/WpiwvVVYqU

[Delong Liu, MD, PhD @JHOeditor]

Cytokine release syndrome: grading, modeling, and new therapy https://t.co/S1Aae7L2D5

[Delong Liu, MD, PhD @JHOeditor]

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Journal of Hematology & Oncology201811:104

[Delong Liu, MD, PhD @JHOeditor]

Hi from #ASCO18 !